NASDAQ:VTGN

Vistagen Therapeutics Stock Insider Trading

Healthcare > Biotechnology

Buy VTGN

*Your capital is at risk

$0.560

-0.0199 (-3.43%)

At Close: Jun 03, 2026

VistaGen Therapeutics Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 100.00. In total, the insiders bought 7.56M and sold 0 VTGN shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	100.00
● Buy	7.56M shares
● Sell	0 shares
100% Buy Activity Negligible or No Correlation
No Significant Signals No statistically significant buy or sell signals detected in recent insider data.

Historical Insider Trades

Date	Type	Person	Role	Amount
May 18, 2026 Buy	Common Stock J-Other	Angelov Angel S Insider	Other	0 Value: $0
May 18, 2026 Buy	Stock Option (Right to Buy) A-Award	Angelov Angel S Chief Medical Officer	Officer	150 000 Value: $89.3K
Apr 07, 2026 Buy	Incentive Stock Option (right to buy) A-Award	Cote Elissa S. Chief Corp Development Officer	Officer	75 000 Value: $40.2K
Apr 07, 2026 Buy	Incentive Stock Option (right to buy) A-Award	Prince Joshua S. Chief Operating Officer	C-Suite Officer	18 752 Value: $10.0K
Apr 07, 2026 Buy	Non-Qualified Stock Option (right to buy) A-Award	Singh Shawn President And CEO	CEO / President	71 268 Value: $38.2K
Apr 07, 2026 Buy	Incentive Stock Option (right to buy) A-Award	Tressler Nick B. Chief Financial Officer	C-Suite Officer	75 000 Value: $40.2K
Apr 07, 2026 Buy	Incentive Stock Option (right to buy) A-Award	Singh Shawn President And CEO	CEO / President	3 732 Value: $2K
Apr 07, 2026 Buy	Non-Qualified Stock Option (right to buy) A-Award	Prince Joshua S. Chief Operating Officer	C-Suite Officer	56 248 Value: $30.1K
Apr 07, 2026 Buy	Non-Qualified Stock Option (right to buy) A-Award	Adler Reid G. Chief Legal Officer	Officer	56 247 Value: $30.1K
Apr 07, 2026 Buy	Incentive Stock Option (right to buy) A-Award	Adler Reid G. Chief Legal Officer	Officer	18 753 Value: $10.0K
Dec 31, 2025 Buy	Common Stock A-Award	Prince Joshua S. Chief Operating Officer	C-Suite Officer	4 386 Value: $2K
Dec 01, 2025 Buy	Common Stock (Right to Buy) A-Award	Tressler Nick B. Chief Financial Officer	C-Suite Officer	150 000 Value: $664.5K
Dec 01, 2025 Buy	Common Stock J-Other	Tressler Nick B. Insider	Other	0 Value: $0
Oct 27, 2025 Buy	Common Stock J-Other	Edick Paul R Insider	Other	0 Value: $0
Oct 27, 2025 Buy	Stock Option (Right to Buy) A-Award	Edick Paul R Director	Director	35 200 Value: $137.3K
Sep 09, 2025 Buy	Non-Qualified Stock Option (right to buy) A-Award	Saxe Jon S Director	Director	17 600 Value: $63.5K
Sep 09, 2025 Buy	Non-Qualified Stock Option (right to buy) A-Award	Rotunno Mary L. Director	Director	17 600 Value: $63.5K
Sep 09, 2025 Buy	Non-Qualified Stock Option (right to buy) A-Award	Fitzpatrick Margaret M Director	Director	17 600 Value: $63.5K
Sep 09, 2025 Buy	Non-Qualified Stock Option (right to buy) A-Award	Curley Joanne Director	Director	17 600 Value: $63.5K
Sep 09, 2025 Buy	Non-Qualified Stock Option (right to buy) A-Award	Cunningham Ann Michelle Director	Director	17 600 Value: $63.5K
Sep 09, 2025 Buy	Non-Qualified Stock Option (right to buy) A-Award	Cunningham Ann Michelle Director	Director	17 600 Value: $63.5K
Sep 09, 2025 Buy	Non-Qualified Stock Option (right to buy) A-Award	Curley Joanne Director	Director	17 600 Value: $63.5K
Sep 09, 2025 Buy	Non-Qualified Stock Option (right to buy) A-Award	Fitzpatrick Margaret M Director	Director	17 600 Value: $63.5K
Sep 09, 2025 Buy	Non-Qualified Stock Option (right to buy) A-Award	Rotunno Mary L. Director	Director	17 600 Value: $63.5K
Sep 09, 2025 Buy	Non-Qualified Stock Option (right to buy) A-Award	Saxe Jon S Director	Director	17 600 Value: $63.5K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT VISTAGEN THERAPEUTICS INC

VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing various medicines with the potential to care for anxiety, depression, and other disorders of the central nervous system (CNS). The company's CNS pipeline includes PH94B, a rapid-onset neuroactive nasal spray, which is in Phase III development for the acute treatment of anxiety in adults with social anxiety disorder. Its PH94B product...

Read Full Profile Here